• View Press Releases

    View Press Releases

News & Media

Recent News

Seattle Genetics Announces Additional Clinical Collaborations to Evaluate SGN-LIV1A in Triple Negative Breast Cancer More

Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer More

Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer More

View All News

Quick Facts

Year founded 1998

Nasdaq SGEN

Number of Employees 1,000+

Global Headquarters Bothell, WA

European Headquarters Zug, Switzerland


Primary Product ADCETRIS® (brentuximab vedotin)


Disease Focus Areas Hodgkin lymphoma, non-Hodgkin lymphoma, urothelial cancer, breast cancer, acute myeloid leukemia


Clinical & preclinical pipeline programs 12+

ADCs in clinical trials using our technology 20+


Social Media


Media Contacts

For Media Professionals Only

Brandi Robinson

Sr. VP, Corporate Communications